Background: Thyroid transcription factor-1 (TTF-1) is expressed in approximately 70% of lung adenocarcinomas and one the most reliable makers to distinguish primary adenocarcinoma from metastatic disease. TTF-1-negative status a poor prognostic factor, associated with efficacy immune checkpoint inhibitor (ICI) monotherapy. However, relationship between TTF-1 expression ICI plus chemotherapy sti...

A reductioii in leparin-activated clearing factor has been demonistrated in individuals with atheroselerosis or conditions related to it. The recent isolation fromn normal plasmlla of an inhibitor to clearing factor suggested that the reduction described mllight be due to .in increased level of inhibitor. This possibility was therefore investigated by determiiiilug the inhibitor efTect of tile ...

A target-based approach has been used to develop novel drugs in many therapeutic fields. In the final stage of intracellular signaling, transcription factor-DNA interactions are central to most biological processes and therefore represent a large and important class of targets for human therapeutics. Thus, we focused on the idea that the disruption of protein dimers and cognate DNA complexes co...

TFPI is a multivalent, Kunitz-type proteinase inhibitor, which, due to alternative mRNA splicing, is transcribed in three isoforms: TFPIalpha, TFPIdelta, and glycosyl phosphatidyl inositol (GPI)-anchored TFPIbeta. The microvascular endothelium is thought to be the principal source of TFPI and TFPIalpha is the predominant isoform expressed in humans. TFPIalpha, apparently attached to the surface...

Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...

Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...

Recent studies of the anticoagulant activities of the tissue factor (TF) pathway inhibitor (TFPI) isoforms, TFPIα and TFPIβ, have provided new insight into the biochemical and physiological mechanisms that underlie bleeding and clotting disorders. TFPIα and TFPIβ have tissue-specific expression patterns and anticoagulant activities. An alternative splicing event in the 5' untranslated region al...

The treatment of acquired haemophilia is characteristically exceedingly expensive and thus a cost-benefit analysis of the several available treatment strategies is urgently needed. To address this issue, decision-analysis techniques were used to construct a cost-minimization model to compare the cost of treatment with porcine factor VIII (pFVIII), human FVIII (hFVIII) or an activated prothrombi...

background : to determine the role of letrozole, an aromatase inhibitor,in the treatment of endometriotic pain.   methods: in this prospective, randomized, controlled clinical trial in minimallyinvasive surgery research center,51 women with pelvic endometriosis and endometriotic pain (dyspareunia, dysmenorrhea, pelvic pain) score of 5 or more (for at least one of these endometriotic pain), afte...

angioedema is an asymmetric non-pitting oedema on face, lips, tongue and mucous membranes; any delay in diagnosis and treatment can be fatal. treatment with lisinopril as an angiotensin converting enzyme (ace) inhibitor, can be a reason of angioedema. here we report a case who developed oral-facial edema four years after using lisinopril/hydrochlorothiazide. laryngeal oedema is a main cause of ...